Core Viewpoint - IREN Limited is expected to see improved efficiency in bitcoin mining, with a decrease in energy consumption from 16 J/TH in Q3 2024 to 15 J/TH in Q3 2025, which is viewed as a significant positive development for the company [1]. Group 1 - The company is positioned favorably due to advancements in mining efficiency, which could enhance profitability and competitiveness in the market [1]. - The analyst emphasizes a unique investment approach called "First Principles," focusing on breaking down complex financial and technological problems to identify overlooked investment opportunities [1]. - The analyst has a strong background in investment, private equity, and venture capital, indicating a solid foundation for delivering insights and potential returns [1].

2025 年 06 月 22 日 行业研究 评级：推荐(维持) 研究所： 证券分析师： 李永磊 S0350521080004 liyl03@ghzq.com.cn 证券分析师： 董伯骏 S0350521080009 dongbj@ghzq.com.cn 证券分析师： 杨丽蓉 S0350524090008 yanglr@ghzq.com.cn 最近一年走势 | 行业相对表现 | | | 2025/06/20 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 基础化工 | -2.4% | -3.2% | 8.8% | | 沪深 300 | -1.3% | -3.2% | 9.8% | 相关报告 《基础化工行业周报：烯草酮、TDI 价格上涨，重 点关注铬盐和磷矿石行业（推荐）*基础化工*李永 磊，董伯骏，杨丽蓉》——2025-05-25 《基础化工行业动态研究：孟山都存破产可能，国 内草甘膦和草铵膦企业有望受益（推荐）*基础化 工*李永磊，董伯骏，杨丽蓉》——2025-05-22 《基础化工行业周报：金属铬、聚合 MDI、烯草酮 价格上涨，重视铬盐大周期（推荐 ...

证券研究报告 | 行业定期报告 2025 年 06 月 22 日 证券研究报告 | 行业定期报告 2025 年 06 月 22 日 火电发电量由降转增，第二产业用电量增速环比下滑 环保公用事业行业周报（2025/06/22） 周期/环保及公用事业 本周环保与公用事业板块均有下跌。环保（申万）行业指数下跌 2.51%，相对 行业整体跌幅较大；公用事业（申万）行业指数下跌 1.13%，跌幅相对较小。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 240 | 4.7 | | 总市值（十亿元） | 3770.3 | 4.4 | | 流通市值（十亿元） | 3513.5 | 4.5 | 行业指数 % 1m 6m 12m 绝对表现 -0.8 1.1 17.4 相对表现 0.5 3.1 7.6 资料来源：公司数据、招商证券 -20 -10 0 10 20 30 Jun/24 Oct/24 Feb/25 May/25 (%) 环保及公用事业 沪深300 luxiangxue@cmschina.com.cn 敬请阅读末页的重要说明 ❑ 本周环保与公用事业板块均有 ...

报告深入剖析了当前智慧养老产品市场"叫好不叫座"的困境，揭示了需求端"不会用、不敢用、不愿 用"的认知鸿沟与供给端"重技术、轻应用"的路径依赖。 真正的智慧养老是科技与人文的双向奔赴。浙江大学管理学院老龄化与养老产业研究中心主任邢以群在 报告解读时表示，报告旨在为行业解答"如何让阳春白雪的'智慧炫品'，转化为触手可及的'生活日用 品'"这一核心问题，并提出"需求定义产品、场景驱动创新、生态共建价值"的破局之道。 在主旨演讲环节，浙江省物联网产业协会副理事长兼秘书长纪卫平以"智慧健康养老智能终端标准及应 用"为题，松下电气(中国)有限公司住建空间事业部代表柳川博人以"共同推进智能科技的高品质发展"为 题，分别分享了行业协会和头部企业的最新实践与前瞻思考。 圆桌论坛环节汇聚了养老服务、物联网、健康产业、养老运营及地产开发等领域的代表，围绕"跨界对 话与共谋发展"主题展开深入探讨，共同探索智慧养老产业的发展路径。(完) 中新网杭州6月22日电(曹丹)6月22日，"浙江省老龄化与老龄产业发展论坛暨2025年中国养老产业商学 研究报告发布会"在浙江杭州举行。本次论坛聚焦"智慧养老产品"专题，深入探讨如何推动科技力量加 ...

国际资金配置仍处于历史低位附近。 年初时，DeepSeek的崛起带动"中国资产重估"，此后这一主题不再局限于科技互联网行业，中国新消费 和创新药都有所表现，而这三大主题也在今年引领了港股行情。 不过，缪子美认为，从估值角度来看，目前MSCI中国指数PE（市盈率）为11倍，PB（市净率）为1.4 倍（近10年低位）；标普500的PE为20倍以上，纳斯达克100的PE为25倍以上。可见，港股的绝对估值 处于历史低位，而美股估值处于历史高位。 同时，美股的高估值依赖于AI叙事，但盈利转化尚未完全兑现。例如，美国科技龙头ROE（净资产收 益率）为33.9%。港股科技股的动态PE（17.4倍）与盈利增速（2025年预期增长19.8%）更匹配，且AI 应用落地可能带来超预期盈利。 投行的数据显示，当前国际资金对中国的配置比例仍处于历史低位附近，但摩根士丹利近期也提及，大 多数全球投资者都明确表示，有意愿重新增配部分中国资产。 在美国资管巨头骏利亨德森投资（Janus Henderson Investors）大中华区股票负责人、基金经理缪子美 （Victoria Mio）看来，那些有创新和突破的行业企业会受重估，例如，能运 ...

买入|首次覆盖 个股表现 -40% -20% 0% 20% 40% 60% 2024-06 2024-09 2024-11 2025-01 2025-04 周大福 恒生指数 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（港元元） | 12.76 | | | | --- | --- | --- | --- | | 总股本/流通股本（亿股）99.88 | | | | | 总市值/流通市值（亿港 | 1,274.44 | | | | 元） | | | | | 52 周内最高/最低价 | 13.72 / 6.43 | | | | 资产负债率(%) | 69.8875 | | | | 市盈率 | 22.1518 | | | | Chow 第一大股东 | | Tai | Fook | | Capital Limited | | | | 研究所 分析师:李鑫鑫 SAC 登记编号:S1340525010006 Email:lixinxin@cnpsec.com 证券研究报告：纺织服饰 | 公司点评报告 发布时间：2025-06-22 股票投资评级 周大福 (1929.HK) 产品结构优化，同店逐季改善 ⚫ 事 ...

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, specifically related to alleged misstatements in financial reporting [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2]. - Investors who purchased Compass securities are encouraged to seek additional information and may have until July 8, 2025, to request to lead the case [2]. Group 2: Allegations Against Compass - The complaint alleges that Compass's fiscal 2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable related to Lugano Holdings, Inc. [3]. - Compass is a statutory trust that manages a portfolio of small and middle-market businesses, including Lugano Holdings, a high-end jewelry designer and manufacturer [3]. Group 3: Stock Market Reaction - Following the announcement on May 7, 2025, that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, Compass's stock price fell approximately 62%, from $17.25 per share to $6.55 per share [4]. - The company indicated that it had identified irregularities in Lugano's financing, accounting, and inventory practices, leading to the resignation of Lugano's founder and CEO without severance compensation [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant cut in the dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Allegations of Misrepresentation - Elevance allegedly misrepresented its monitoring of cost trends associated with the Medicaid redetermination process and the sufficiency of negotiated rates to address patient risk profiles [4]. - The redetermination process reportedly caused a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial performance and operational challenges [6].